Skip to main content

Lineage Cell Therapeutics, Inc 8-K, filed Nov 12, 2026

Lineage Cell Therapeutics, Inc. (LCTX)

8-K 2026-11-12 For: 2026-11-12
View Original
Added on November 13, 2026

About this 8-K

Lineage Cell Therapeutics, Inc filed this 8-K on November 12, 2026.

Lineage acquired NeuroAirmid on November 12, 2026, adding HUNT1, a Phase 1b/2a Huntington’s Disease cell therapy. Closing consideration included $2.4 million in cash, 2.2 million common shares, and up to $48.0 million in clinical and regulatory milestones. AI summary

Items reported

  • Item 1.01: Entered into a material agreement
  • Item 2.01: Completed an acquisition or sale of assets
  • Item 2.02: Financial results
  • Item 3.02: Unregistered sale of equity
  • Item 7.01: Regulation FD disclosure
  • Item 9.01: Financial statements and exhibits